Startup · United Kingdom
LabGenius Therapeutics
HQ London, United KingdomFounded 201251-200 employeesUpdated
Uses machine learning to develop therapeutic antibodies.
Funding7 rounds · ~$86.5M
- Equity raised
- ~$86.5M
- Debt, secondaries & grants
- Undisclosed
- Latest
- $64KStage undisclosed · Feb 9, 2026
| Announced | Stage | Amount | Valuation | Lead investors | Other investors | Confidence |
|---|---|---|---|---|---|---|
| Feb 9, 2026 | Undisclosed | $64K | — | — | — | Reported |
| Jul 31, 2025 | Series B | $13.5M | — | M Ventures | — | Reported |
| May 21, 2024 | Series B | ~$44.2M | — | M Ventures | Atomico, Lux Capital, Obvious Ventures | Confirmed |
| Nov 30, 2022 | Grant | Undisclosed | — | Innovate UK | — | Reported |
| Oct 29, 2020 | Series A | $15.0M | — | Atomico | Kindred Capital, Lux Capital, Obvious Ventures | Reported |
| Oct 23, 2019 | Series A | $10.0M | — | Lux Capital, Obvious Ventures | Air Street Capital, Felicis | Reported |
| Nov 27, 2017 | Seed | $3.7M | — | Acequia Capital, Kindred Capital | — | Reported |
- Undisclosed$64KFeb 9, 2026
- Series BLed by M Ventures$13.5MJul 31, 2025
- ~$44.2MMay 21, 2024
- GrantLed by Innovate UKUndisclosedNov 30, 2022
- $15.0MOct 29, 2020
- $10.0MOct 23, 2019
- SeedLed by Acequia Capital, Kindred Capital$3.7MNov 27, 2017
Raised counts equity rounds; debt, secondary sales and grants are totaled separately. Amounts in other currencies are converted at the announcement month's average rate. A ~ marks an estimated or converted amount.
Systems1
- LGTX-101A therapeutic T-cell-engager antibody candidate.
Newest unveiled first. Systems that belong to a government program link to the program page, where variants, costs and contracts are.
People4
| Person | Role |
|---|---|
| Angus Sinclair · LinkedIn ↗ | Chief Scientific Officer |
| Dr. Didier Landais | Chief Operating Officer |
| Hannah Seitz | Chief Business Officer |
| James Field · LinkedIn ↗ | Chief Executive Officer |
Sources16
Show all 16 sources and supporting evidence
Profile2
- 1
LabGenius Therapeutics · Supports Organization · description, Organization · name, Organization · website
“Combining human and machine intelligence to discover the next generation of therapeutic antibodies.”
- 2
Sixth-Domain · Supports Organization · kind
“{"group": "startups", "id": "3ee4cbf8-3434-4187-a97f-a14bc0d9f429", "name": "LabGenius"}”
Systems1
- 3
LabGenius Therapeutics · Supports System
“Through the tight integration of high-throughput functional cell-based experimentation with machine learning (ML), LabGenius’ proprietary lead optimisation platform (*EVA™*) generated a highly selective and potent trivalent VHH-based Nectin-4 x CD3 T-cell engager (TCE), LGTX-101”
Funding12
- 4
LabGenius · May 21, 2024 · Supports Funding round · amount
“has closed a £35 million Series B financing round”
- 5
FinSMEs · May 21, 2024 · Supports Funding round
“The round was led by M Ventures”
- 6
EU-Startups · Oct 23, 2019 · Supports Funding round
“The Series A investment round was led by Lux Capital and Obvious Ventures”
- 7
FinSMEs · Oct 23, 2019 · Supports Funding round · amount
“LabGenius Raises $10M in Series A Funding”
- 8
UKTN · Nov 27, 2017 · Supports Funding round
“The Seed round was led by Kindred Capital and Acequia Capital”
- 9
Nordic9 · Supports Funding round · amount
“announced that it closed a $15M extension round”
- 10
PitchBook · Supports Funding round, Funding round · amount, Organization · country, Organization · employee range, Organization · founded year, Organization · linkedin url, Organization · ownership, Organization · x url
“8\. Grant | 30-Nov-2022”
- 11
- 12
VentureBeat · Supports Funding round
“has been awarded a highly competitive Biomedical Catalyst (BMC) grant from Innovate UK”
- 13
Crunchbase · Supports Funding round
“Series B”
- 14
FinSMEs · Supports Funding round · amount
“raised $3.66m in seed funding”
- 15
LinkedIn · Supports Funding round, Organization · country, Organization · employee range, Organization · founded year, Organization · hq city, Organization · linkedin url, Role
“funding round: Venture Round, 2026-02-09, USD 64,166”
People1
- 16
LabGenius Therapeutics · Supports Role
“Angus Sinclair Chief Scientific Officer”
Each fact on this page is attached to the sources that support it. Archived copies are linked when we keep one.